Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Gross Profit (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Gross Profit for 17 consecutive years, with $146.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Gross Profit fell 2.72% to $146.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $576.6 million, a 1.5% decrease, with the full-year FY2025 number at $576.6 million, down 1.5% from a year prior.
  • Gross Profit was $146.8 million for Q4 2025 at Myriad Genetics, up from $143.8 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $151.8 million in Q2 2025 to a low of -$89.0 million in Q4 2022.
  • A 5-year average of $119.7 million and a median of $131.9 million in 2025 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: crashed 177.39% in 2022, then soared 192.13% in 2023.
  • Myriad Genetics' Gross Profit stood at $115.0 million in 2021, then plummeted by 177.39% to -$89.0 million in 2022, then skyrocketed by 192.13% to $82.0 million in 2023, then soared by 84.02% to $150.9 million in 2024, then fell by 2.72% to $146.8 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Gross Profit are $146.8 million (Q4 2025), $143.8 million (Q3 2025), and $151.8 million (Q2 2025).